

## BioMime™ Morph TECHNICAL SPECIFICATIONS

### STENT

Stent Material	: Cobalt Chromium L605
Strut Thickness	: 65 µm (0.065mm or 0.0026")
Stent Diameters (mm)	: 2.75-2.25, 3.00-2.50, 3.50-2.75, 3.5-3.00
Stent Lengths (mm)	: 30, 40, 50, 60
Mean Recoil	: <4%
Mean Foreshortening	: <1%

### DRUG / POLYMER

Drug	: Sirolimus
Equivalent Drug Dose	: 1.25 µg / mm <sup>2</sup>
Polymer	: Biodegradable and Biocompatible

### DELIVERY SYSTEM

Delivery System	: Rapid Exchange
Stent Diameter	: Crossing Profile
mm	mm / inches
2.75-2.25	0.93 / 0.037"
3.00-2.50	0.99 / 0.039"
3.50-2.75	1.03 / 0.040"
3.50-3.00	1.03 / 0.040"
Nominal Pressure	: 9 atm
Rated Burst Pressure	: 14 atm (Refer IFU for more details)
Balloon Overhang	: ≤ 0.5 mm
Shaft Outer Diameter	: Proximal: 2.13 F, Distal: 2.7 F (Refer IFU for more details)
Radiopaque Markers	: 2 - Platinum / Iridium
Usable Catheter Length	: 142 cm
Guide Catheter Compatibility	: 5F (Min. I. D. 0.056" / 1.42 mm)
Max. Guidewire	: 0.014" (0.36 mm)

## BioMime™ Morph ORDERING INFORMATION

Diameter	Length			
	30 mm	40 mm	50 mm	60 mm
2.75-2.25 mm	BIM27522530	BIM27522540	BIM27522550	BIM27522560
3.00-2.50 mm	BIM30025030	BIM30025040	BIM30025050	BIM30025060
<b>3.50-2.75 mm</b>	<b>BIM35027530</b>	<b>BIM35027540</b>	<b>BIM35027550</b>	<b>BIM35027560</b>
3.50-3.00 mm	BIM35030030	BIM35030040	BIM35030050	BIM35030060

Contact your country local Meril sales representative for availability of sizes highlighted in blue



More to Life

#### Manufacturer:

**Meril Life Sciences Pvt. Ltd.**  
Survey No. 135/139, Bilakhia House,  
Muktanand Marg, Chala, Vapi - 396 191.  
Gujarat, India.  
T +91 260 240 8000

#### Subsidiary companies:

**Meril Life Sciences Pvt. Ltd.**  
301, A-Wing, Business Square,  
Chakala, Andheri Kurla Road,  
Andheri East, Mumbai 400 093  
T +91 22 39350700  
F +91 22 39350777

#### Meril, Inc.

2436 Emrick Boulevard,  
Bethlehem, PA 18020  
T +610 500 2080  
F +610 317 1672

#### Meril South America

Doc Med LTDA  
Al. dos Tupiniquins,  
1079 - Cep: 04077-003 - Moema,  
Sao Paulo, Brazil.  
T +55 11 3624 5935  
F +55 11 3624 5936

#### Meril GmbH.

Bornheimer Strasse 135-137,  
D-53119 Bonn,  
Germany.  
T +49 228 7100 4000  
F +49 228 7100 4001

#### Meril Tibbi Cihazlar

Meril Tibbi Cihazlar İmalat ve Ticaret A.Ş.  
İçerenköy Mah. Çetinkaya Sok.  
Prestij Plaza No:28  
Kat:4 Ataşehir, 34752  
İstanbul / Turkey  
T +90 216 641 44 24  
F +90 216 641 44 25

#### Meril China Co. Ltd.

2301b,23f, Lixin Plaza,  
no 90, South Hubin Road,  
Xiamen, China  
T 0086-592-5368505  
F 0086-592-5368519

#### Meril SA Pty. Ltd.

102, 104, S101 and S102,  
Boulevard West Office Park,  
142 Western Service Road,  
Erf 813 Woodmead Extension 17  
Sandton, Johannesburg – 2191  
South Africa  
T +27 11 465-2049  
F +27 86 471 7941

#### Meril Medical LLC.

Nauchnyi Proezd 19,  
Moscow, Russia – 117 246.  
Office - +7 495 772 7643

#### EU representative.

Obelis S.A.  
Bd, General Wahis 53,  
1030, Brussels, Belgium.  
T +32 2 732 5954  
F +32 2 732 6003  
E mail@obelis.net

E askinfo@merillife.com  
W www.merillife.com

For the use of a Registered Medical Practitioner of Hospital or Laboratory only

BIM/BROCHURE/004/MLS/20200907/GLOBAL



Cardiovascular



**biomime™ morph**

Sirolimus Eluting Coronary Stent System

Morphs so well, you can tell

Natural arteries taper, so should your stent

# World's 1<sup>st</sup> Tapered Drug-Eluting Stent System

**biomime<sup>TM</sup> morph**

Sirolimus Eluting Coronary Stent System

Morphs so well, you can tell


**Avoid overlapping and associated restenosis and revascularization**

**Reduce procedural time as single stent is deployed**

**Avoid excessive radiation and contrast**

**Economical one stent versus use of multiple overlapping stents**

Proximal Ø (mm)



Lengths - 30, 40, 50, 60 mm

## Morpheus-Global study\*:

BioMime Morph SES system demonstrates favorable clinical outcomes in very long coronary lesions(≤56mm) at six-month clinical follow-up in a real-world global registry

31.7% diabetic, 68.2% very long lesions(≥46mm), 34.9% CTO, 82.4% B2/C lesion

Events, n (%)	In-hospital (n=482)	1-month follow-up (n=470)	6-month follow-up (n=350) (Interim results)
Cardiac death	0(0.0)	2(0.4)	4(1.1)
MI	1(0.2)	2(0.4)	3(0.9)
ID-TLR	0(0.0)	2(0.4)	7(2.0)
Definite ST	0(0.0)	2(0.4)	2(0.6)
MACE	1(0.2)	6(1.3)	14(4.0)
Freedom from TLF	481(99.8)	464(98.7)	336(96.0)

\*Source : Interim results presented by Dr. P. Agostoni on behalf of Morpheus-Global Investigators during the Late-breaking Trial session at EuroPCR 2019.

### Flexibility

Novel Hybrid Design with Closed cells (on both ends of the stent) & Open cells (in the middle)

### Side-Branch Access

Stent design with non-linear S links & Y connectors allows for high flexibility and adequate side branch access

### Radial Strength

Strut width variability ensures optimal radial strength

Values are presented in n (%), MI=Myocardial Infarction, ID-TLR = Ischemia-Driven Target Lesion Revascularization, ST=Stent Thrombosis, MACE=Major Adverse Cardiac Event, TLF=Target Lesion Failure